News Releases

Date	Title
Jun 29, 2022	Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
Jun 13, 2022	Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
May 18, 2022	Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
May 16, 2022	Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
May 02, 2022	Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
Apr 21, 2022	Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
Mar 23, 2022	Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Mar 10, 2022	Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
Mar 03, 2022	Homology Medicines to Participate in Upcoming Investor Conferences
Feb 18, 2022	Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU